Drugs / 9MW1411
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04784312 | Apr → Aug 2021 | staphylococcus aureus infection | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05339802 | Feb 2022 → Oct 2023 | skin infection | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW1411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05339802 ↗ |
| Route | Intravenous | “administered as a single IV dose” NCT04784312 ↗ |